Phylogica : 600% Effective

Always good to get a pearl out of Phylogica (ASX : PYC) informing us that their latest “petri dish” experiment works 600% better than a previous “petri dish” experiment. Also nice to see approximately 600% abuse of ASX continuous disclosure rules… Instead of writing yet another rant about PYC’s rubbish in vitro studies, I am going to…

A big idea for Phylogica…

Hands down, Phylogica (ASX : PYC) is one of the most wasteful, pointless and irrelevant ASX-listed biotech companies. I have previously written about this utter farce of a company and frankly speaking, I had nothing to add to the discussion when PYC announced their successful fundraising last week of ~$10m smackeroos. I had nothing positive…

Compensation Matters

I have alluded to my distaste for excessive executive and board compensation several times since I started this blog. For example, my opinion is generally known that Geoff Cumming at Anteo Diagnostics (ASX : ADO) is considerably overpaid relative to the performance of his company, particularly revenue growth. Compensation  is also a multi-faceted beast and so…

It’s just not Phylogical…

What a truly lousy company. Several regular Long Tail readers have gloatingly reminded me today how gentle I was the last time I wrote about Phylogica (ASX : PYC), many moons ago. I guess it was the early days of The Long Tail and I was still trying to find hope in the world of ASX-listed biotech. After having read…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…

The Shock Jock : Market Roundup

You give me a royal pain in the ass, if you want to know the truth. – Holden (J.D. Salinger) When I announced earlier in the week that I would no longer be commenting on HotCopper, I thought that would be the end of the annoying, low-intelligence comments mostly aimed at some degree of personal…

Take THAT, Cancer Cells! (PYC)

That’s how it goes – you turn your back for a long weekend and something crazy happens. Like Phylogica (ASX: PYC). I bemoan the loss of the rare opportunity to own stock in a company that rocketed about 90% on the announcement of a successful pilot (more on that milestone in a minute). Perhaps the punters…